News

The acquisition will add to Clinigen’s existing footprint in the country following the launch of its Japanese business in October 2016. The acquisition of IMMC is part of

The company has taken the decision based on three proof-of-concept studies, which does not show clinically meaningful efficacy results. The studies comprised of Phase 1 study in healthy

Tafinlar in combination with Mekinist is in development to become the first adjuvant treatment specifically for melanoma patients with a BRAF V600 mutation. The designation is based on

Both existing and new investors, including Auven Therapeutics, Redmile, the Wild Family Office and AstraZeneca oversubscribed and supported the financing. ADCT develops antibody drug conjugates (ADCs) that target

The firm has decided to terminate the trials based on the recommendation of the data monitoring committee, which evaluated overall benefit/risk during a recent interim futility analysis. Celgene

Additionally, Aurinia announced plans to evaluate its proprietary nanomicellar voclosporin ophthalmic solution (VOS) for the treatment of keratoconjunctivitis sicca or dry eye syndrome (DES). The advancement of these

Today’s approvals follow the first FDA approval of SIMPONI ARIA in 2013 for the treatment of moderately to severely active rheumatoid arthritis (RA). The PsA and AS approvals are

The non-live, recombinant subunit vaccine has been indicated to be given intramuscularly in two doses. Shingrix, which combines glycoprotein E antigen with the AS01B adjuvant system, works by

TARGET-NASH is a longitudinal observational study that evaluates patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). To date, TARGET-NASH has enrolled 2,423 patients at 55